D. Boral Capital Maintains Buy on Citius Pharmaceuticals, Maintains $6 Price Target

Benzinga · 1d ago
D. Boral Capital analyst Jason Kolbert maintains Citius Pharmaceuticals (NASDAQ:CTXR) with a Buy and maintains $6 price target.